Etsuro Bando1, Rie Makuuchi1, Masanori Tokunaga1, Yutaka Tanizawa1, Taiichi Kawamura1, Masanori Terashima2. 1. Division of Gastric Surgery, Shizuoka Cancer Center, Shimonagakubo 1007, Nagaizumichou, Suntougun, Shizuoka, 411-0934, Japan. 2. Division of Gastric Surgery, Shizuoka Cancer Center, Shimonagakubo 1007, Nagaizumichou, Suntougun, Shizuoka, 411-0934, Japan. m.terashima@scchr.jp.
Abstract
BACKGROUND: Preoperative clinical staging of gastric cancer is used to determine therapeutic strategies. However, the impact of the clinical stage on survival has not been completely investigated, although the relationship between pathologic staging and survival outcome has been reported. The aim of the present study was to clarify the predictability of patient survival based on clinical staging and to evaluate the usefulness of staging as an indicator for selecting the treatment modality. METHODS: A total of 3033 patients who underwent surgery for gastric cancer were included. A survival analysis was conducted based on the seventh edition of the tumor-node-metastasis (TNM) clinical staging system of the American Joint Committee on Cancer. The predictive ability of the TNM clinical stage for survival was evaluated by Harrell's C-index, a measure of the separation of survival distributions. RESULTS: The cumulative 5-year survival rates according to the clinical stage were 94.3 % (IA), 84.7 % (IB), 71.7 % (IIA), 56.1 % (IIB), 55.7 % (IIIA), 42.3 % (IIIB), 22.8 % (IIIC), and 9.1 % (IV). Although no significant difference was observed between clinical stages IIB and IIIA (p = 0.865), significant differences existed between all other clinical stages (p < 0.001). Harrell's C-index applied to these results was 0.825 (95 % confidence interval 0.819-0.831). CONCLUSIONS: The seventh edition of the TNM clinical staging system has a strong prognostic ability with a satisfactory C-index and should be considered valuable for selecting therapeutic strategies for the treatment of gastric cancer.
BACKGROUND: Preoperative clinical staging of gastric cancer is used to determine therapeutic strategies. However, the impact of the clinical stage on survival has not been completely investigated, although the relationship between pathologic staging and survival outcome has been reported. The aim of the present study was to clarify the predictability of patient survival based on clinical staging and to evaluate the usefulness of staging as an indicator for selecting the treatment modality. METHODS: A total of 3033 patients who underwent surgery for gastric cancer were included. A survival analysis was conducted based on the seventh edition of the tumor-node-metastasis (TNM) clinical staging system of the American Joint Committee on Cancer. The predictive ability of the TNM clinical stage for survival was evaluated by Harrell's C-index, a measure of the separation of survival distributions. RESULTS: The cumulative 5-year survival rates according to the clinical stage were 94.3 % (IA), 84.7 % (IB), 71.7 % (IIA), 56.1 % (IIB), 55.7 % (IIIA), 42.3 % (IIIB), 22.8 % (IIIC), and 9.1 % (IV). Although no significant difference was observed between clinical stages IIB and IIIA (p = 0.865), significant differences existed between all other clinical stages (p < 0.001). Harrell's C-index applied to these results was 0.825 (95 % confidence interval 0.819-0.831). CONCLUSIONS: The seventh edition of the TNM clinical staging system has a strong prognostic ability with a satisfactory C-index and should be considered valuable for selecting therapeutic strategies for the treatment of gastric cancer.
Authors: Abeezar I Sarela; Thomas J Miner; Martin S Karpeh; Daniel G Coit; David P Jaques; Murray F Brennan Journal: Ann Surg Date: 2006-02 Impact factor: 12.969
Authors: Sook Ryun Park; Min Ju Kim; Keun Won Ryu; Jun Ho Lee; Jong Seok Lee; Byung-Ho Nam; Il Ju Choi; Young-Woo Kim Journal: Ann Surg Date: 2010-03 Impact factor: 12.969
Authors: Seok-Ki Kim; Keon Wook Kang; Jong Seok Lee; Hark Kyun Kim; Hee Jin Chang; Jin Yi Choi; Jun Ho Lee; Keun Won Ryu; Young-Woo Kim; Jae-Moon Bae Journal: Eur J Nucl Med Mol Imaging Date: 2005-10-15 Impact factor: 9.236
Authors: Haejin In; Ethan Ravetch; Marisa Langdon-Embry; Bryan Palis; Jaffer A Ajani; Wayne L Hofstetter; David P Kelsen; Takeshi Sano Journal: Gastric Cancer Date: 2017-09-25 Impact factor: 7.370
Authors: Etsuro Bando; Xinge Ji; Michael W Kattan; Ho Seok Seo; Kyo Young Song; Cho-Hyun Park; Maria Bencivenga; Giovanni de Manzoni; Masanori Terashima Journal: Cancer Med Date: 2020-06-26 Impact factor: 4.452
Authors: Etsuro Bando; Xinge Ji; Michael W Kattan; Maria Bencivenga; Giovanni de Manzoni; Masanori Terashima Journal: Cancer Med Date: 2021-10-10 Impact factor: 4.452